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The aim of the study conducted by 
Rosenbach et al. (2009, this issue) is 
important, because validated tools to 
assess pemphigus severity and responses 
to treatment are essential for multicenter 
controlled trials and for comparing the 
results of different trials. Many treat-
ments for pemphigus exist, but few 
controlled randomized studies of the 
efficacy of these treatments have been 
reported (Martin et al., 2006). Moreover, 
various studies have used different out-
comes, including complete healing of 
lesions, duration of remission, number 
of recurrences, and time to inhibition of 
disease progression. Therefore, a major 
obstacle in comparing therapeutic out-
comes in pemphigus is the lack of gen-
erally accepted outcome instruments by 
which to measure them.
The validity of scoring methods in 
pemphigus has not been thoroughly 
investigated. The lack of well-designed 
studies might be related to the rarity of 
the disease. Indeed, in recent European 
studies (in France and the United 
Kingdom), pemphigus incidence ranged 
from 0.17 (95% confidence interval: 
0.14–0.21) to 0.7 (0.6–0.8) new cases 
per 100,000 person-years (Bastuji-
Garin et al., 1995; Langan et al., 2008). 
Moreover, pemphigus is clinically het-
erogeneous, with pemphigus vulgaris 
(PV) and pemphigus foliaceus (PF) being 
its two major subtypes. PV is commonly 
more severe than PF (Goon and Tan, 
2001), and therapeutic strategies for 
these conditions usually differ.
Rosenbach et al. (2009) evaluate a 
new outcome instrument for pemphi-
gus, the Pemphigus Disease Area Index 
(PDAI), developed by the International 
Pemphigus Committee (Murrell et al., 
2008). The PDAI aims to assess the 
extent of cutaneous lesions and skin 
involvement; the skin, scalp, and muco-
sa are scored separately. Rosenbach 
and colleagues sought to assess the 
reliability and the convergent validity 
of this new tool by comparing it with 
a recently developed scoring system, 
the Autoimmune Bullous Skin Disorder 
Intensity Score (ABSIS) (Pfutze et al., 
2007), and with the Physician’s Global 
Assessment (PGA), an instrument used 
for inflammatory skin diseases. None of 
these tools had previously been assessed 
for pemphigus. Ten dermatologists with 
extensive experience with pemphigus 
evaluated 15 patients with a diagnosis 
of PV, PF, or paraneoplastic pemphigus. 
The population under study was not 
described, but it appears that only mild 
cases were analyzed. Each physician 
scored the 15 patients and rerated 2 ran-
domly selected patients, with a 2-hour 
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delay between the two evaluations. 
Having determined that reliability and 
convergent validity were adequate, the 
authors concluded that the PDAI could 
be a useful tool.
Therefore, the study by Rosenbach 
et al. (2009) is a first step toward future 
outcome instruments for pemphigus. But 
several weaknesses in the study must be 
addressed before its conclusions can be 
viewed with confidence. Therefore, from 
a methodological point of view, we pro-
pose a filter to evaluate scoring methods 
that takes into account reliability, sen-
sitivity to change, accuracy, feasibility, 
and external validity.
reliability and discrimination
Also called precision, reproducibility, 
and consistency, reliability deals with 
the question “Does the instrument give 
the same value each time it is used?” If 
the first goal of an assessment tool is to 
minimize measurement error, the scor-
ing method should be relatively precise 
(i.e., reliable or free of random error) 
and accurate (i.e., free of systematic 
error). Reliability is affected by random 
error. Depending on the research ques-
tions, the main source of variability 
may be among patients or among the 
physicians who have rated the patients. 
Therefore, reliability is defined as the 
consistency of repeated measurements 
by a single observer on a sample of sub-
jects (intraobserver reliability) and by 
different observers performing measure-
ments on the same sample of subjects 
(inter observer reliability). Intraobserver 
variability describes the reproducibility 
in results achieved when the same 
observer rates at different times with a 
sufficient delay between two scorings 
(generally several days). Interobserver 
variability depends on the physicians’ 
skill and experience, as well as on the 
disease itself. For pemphigus, as for most 
of other dermatological disorders, the 
natural course of the disease precludes 
the use of such a period between two 
ratings. One solution would be succes-
sive rating of the same sets of photo-
graphs. Ideally, investigators should be 
blind to the results of other investigators 
and to their own previous results.
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One of the drawbacks of the study 
presented by Rosenbach et al. (2009) is 
the rerating process, which is not clear-
ly described. Physicians and patients 
were divided into two groups; physi-
cians scored the first group using the 
ABSIS instrument, followed by the PDAI 
and the PGA. They reversed the order of 
tools for the second group. Then, each 
physician returned to the first group and 
rerated two randomly chosen patients, 
at least 2 hours after the initial scoring. 
A rerating 2 hours after the first scor-
ing is potentially open to recall bias, 
but such recall bias cannot be used to 
explain the differences between the two 
scales found in the reported study. With 
each physician having rerated only two 
patients, the sample size is not optimal 
for an expected width of the 95% con-
fidence interval of the intraclass corre-
lation coefficient (ICC; Giraudeau and 
Mary, 2001). Moreover, the mild cases 
used in this study may not be sufficient to 
predict intra- and interobserver reliability 
in a more hetero geneous population.
Inter- and intraobserver reliability 
are usually estimated by the ICC using 
analysis of variance (Shrout and Fleiss, 
1979). However, plotting the score 
using the Bland and Altman method to 
visualize the judges’ agreement, as well 
as any relation between severity of the 
disease and disagreement, is also rec-
ommended (Bland and Altman, 1986). 
This additional method was not used by 
Rosenbach et al. (2009).
Sensitivity to change
An ideal scoring system for rating dis-
ease activity could be used not only 
to determine the best treatment (out-
come instrument) but also to assess ini-
tial severity in order to stratify patients 
according to their status, to assess prog-
nosis, to monitor patients longitudinally, 
and to detect potential relapse. To obtain 
insight into a measurement’s sensitivity 
to change, it should be assessed not only 
at baseline (i.e., before therapy is start-
ed) but also during and following treat-
ment. In addition, the effect size should 
be calculated, allowing the agreement 
(reliability) between two observers on 
progression—or regression—in individ-
ual patients (Tx-T0 data) to be assessed. 
The percentage of patients with any 
change from the baseline and that of 
patients with clinically relevant change 
should be provided. Unfortunately, 
Rosenbach et al. (2009) provide only 
one measurement and omit the time 
precision (baseline, under treatment, 
and others). The aim of the authors was 
to develop outcome instruments, but 
response criteria depend on the defini-
tion of the minimal clinically important 
change. Because such a definition is 
rarely available, a first step is to deter-
mine the smallest detectable differ-
ence in evolution, for which anything 
smaller cannot be reliably distinguished 
from random error in measurement. 
Rosenbach and colleagues rightly 
acknowledge the need for further stud-
ies; they will probably explore sensitiv-
ity to change in future.
accuracy—also called “truth”
Accuracy is best assessed by compar-
ing a measure to a “gold standard,” a 
reference that is considered accurate. 
Because no concrete gold standard 
exists for pemphigus, the authors used a 
particular type of accuracy—convergent 
validity—to assess how well their mea-
surement represents the phenomenon 
of interest. Convergent validity repre-
sents the degree to which a measure is 
similar to (converges on) another mea-
sure to which it should theoretically be 
similar. For instance, to demonstrate the 
convergent validity of a test of math-
ematics skills, the scores on the test can 
be correlated with scores on other tests 
that are also designed to measure basic 
mathematical ability. High correlations 
between the test scores would be evi-
dence of convergent validity. To assess 
convergent validity, the authors used a 
10-point visual analog scale (the PGA) 
that provides a subjective overall evalu-
ation of disease severity. However, they 
report rather poor interobserver reliabil-
ity for the PGA (ICC = 0.44; 0.22–0.65).
The validity of a study also depends 
on how well the variables designed for 
the study represent the phenomenon of 
interest (construct validity). When con-
structing an outcome measurement, the 
first task is to identify a set of items that 
could be included in the final instru-
ment. These items can be selected in 
several ways: by a panel of experts, by 
a comparison with relevant literature, or 
by patients’ opinion of how the disease 
affects their life. Constructing an out-
come instrument consists of selecting 
the most relevant items in terms of con-
tent, adequate level of measurement, 
and avoidance of overlap (Coste et al., 
1995). To our knowledge, the process 
of the construction of the PDAI has not 
been reported (Murrell et al., 2008). It 
is not known whether the same scoring 
system could be applied to both forms 
of pemphigus. Skin and mucosal lesions 
may need to be weighted differently to 
take into account the clinical variability 
of the disease.
Feasibility
Feasibility addresses whether the mea-
sure can be easily applied given the 
constraints of time and resources. 
Therefore, information should be given 
about the time needed for training and 
scoring. The authors reported that the 
mean time for the PDAI was 4.7 (±0.18 
min), which appears reasonable; how-
ever, the majority of physicians involved 
in the study reported that the PDAI was 
too difficult to be incorporated into their 
clinical practice. Whether reducing 
the number of items could improve the 
quality and the efficiency of each item 
should be studied (construct validity).
external validity
As is usual in clinical epidemiology, the 
goal of the report by Rosenbach et al. is 
to draw inferences about populations by 
measuring samples. Sample selection 
and its validity can affect the validity of 
the inferences drawn as a result of the 
study. Spectrum bias occurs when the 
spectrum of the disease in the sample dif-
fers from that of the population to which 
the investigators wish to generalize. 
Randomizing the sample of patients as 
well as those who rate can enhance the 
generalizability of studies, and a scoring 
system assessment should be performed 
on a cross-sectional sample of the 
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population to which the results will later 
be applied. In the present study, neither 
physicians nor patients were randomly 
selected. The convenience sample of 15 
volunteer patients, whose characteristics 
(age, sex, subtypes of pemphigus, time in 
the course of the disease, i.e., before or 
after treatment) are not described, can-
not be assumed to represent patients 
who may be included in future trials. 
The PV-to-PF ratio was not provided—
PV accounts for about two-thirds of all 
pemphigus cases and PF for about 20%. 
These points are important, because 
the clinical characteristics included in 
the scale (mucous membrane involve-
ment), prognosis, and therapeutics dif-
fer between PV and PF, and it is impos-
sible to estimate to which population the 
results could be extrapolated.
Overall, validated outcome mea-
sures are essential for optimal patient 
care. Therefore, the successive research 
work of this International Pemphigus 
Committee is of major importance, and 
this study on outcome instruments for 
pemphigus is a first approach. The assess-
ment of larger, well-defined populations 
with a formal evaluation, including the 
usual successive methodological steps, is 
needed before the PDAI should be used 
as a research instrument.
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Protein Kinase cα Puts the Handcuffs 
on epidermal Keratinocyte Proliferation
Wendy B. Bollag1,2
As the predominant cellular receptor for phorbol esters, protein kinase c (PKc) is 
assumed to play a role in epidermal carcinogenesis. nevertheless, determining its 
exact role in keratinocytes has been difficult because of the existence of multiple 
PKc isoforms and the inherent weaknesses in methodologies used to investigate 
their function. In this issue, Jerome-Morais et al. describe their use of multiple in 
vitro, in situ, overexpression, and knockdown approaches to demonstrate that 
PKcα induces keratinocyte growth arrest.
Journal of Investigational Dermatology (2009) 129, 2330–2332. doi:10.1038/jid.2009.165
The ability of phorbol esters to promote 
tumor formation in mouse epidermis 
preinitiated with a carcinogen led to 
the idea that the phorbol ester target 
in skin must be involved in epidermal 
tumorigenesis. Thus, the identification 
of protein kinase C (PKC) as the primary 
cellular target of phorbol esters suggested 
an important role for PKC in epidermal 
tumor formation, as well as for the biol-
ogy of the keratinocyte, the predominant 
cell in the epidermis (reviewed in Bollag 
and Bollag, 2001). However, despite an 
abundance of studies investigating the 
role of this enzyme in the epidermis, 
both in vitro and in vivo, the exact role of 
PKC in keratinocyte function and epider-
mal tumorigenesis remains unclear.
This imperfect knowledge about the 
role played by PKC in the epidermis is 
likely due in large part to the existence of 
multiple PKC family members, each with 
disparate mechanisms of activation and 
different function (reviewed in Bollag and 
Bollag, 2001). Thus, conventional PKC 
isoenzymes (PKCα, -βI, -βII, and -γ) are 
phospholipid dependent, diacyl glycerol 
activated, and calcium sensitive, where-
as the novel PKC isoforms (PKCδ, -ε, 
-η, and -θ) also require phospholipids 
and are activated by diacylglycerol, but 
they are insensitive to calcium. Atypical 
PKCs (PKCζ and -λ/ι), on the other hand, 
require neither diacylglycerol nor cal-
cium (Figure 1). Because phorbol esters 
can substitute for naturally occurring 
diacylglycerol in activating conven-
tional and novel PKC isoenzymes, the 
ability of phorbol esters to promote epi-
dermal tumor formation indicates the 
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